Processing Deficient Progeroid Laminopathies (PDPL) Latest Advances
Find the Latest Research About Processing Deficient Progeroid Laminopathies (PDPL)
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
National survey of Hutchinson-Gilford progeria syndrome and progeroid laminopathy in Japan.
Journal: Aging
Published: April 02, 2025
The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Journal: Nucleus (Austin, Tex.)
Published: December 05, 2023
The role of prelamin A post-translational maturation in stress response and 53BP1 recruitment.
Journal: Frontiers in cell and developmental biology
Published: August 12, 2022
FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.
Journal: Genetics in medicine : official journal of the American College of Medical Genetics
Published: June 10, 2022
DNA methylation signatures in Blood DNA of Hutchinson-Gilford Progeria syndrome.
Journal: Aging cell
Published: September 01, 2021
Protein structural and mechanistic basis of progeroid laminopathies.
Journal: The FEBS journal
Published: May 23, 2020
Looking at New Unexpected Disease Targets in LMNA-Linked Lipodystrophies in the Light of Complex Cardiovascular Phenotypes: Implications for Clinical Practice.
Journal: Cells
Published: February 03, 2020
The Cutting Edge: The Role of mTOR Signaling in Laminopathies.
Journal: International journal of molecular sciences
Published: January 21, 2019
Last Updated: 04/28/2026